Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts

Molecular Cancer Therapeutics

Volumn 3, Issue 2, 2004, Pages 111-121

  Bani, Maria Rosa ^a   Nicoletti, Maria Ines ^a   Alkharouf, Nawal W ^b   Ghilardi, Carmen ^a   Petersen, David ^b   Erba, Eugenio ^a   Sausville, Edward A ^b   Liu, Edison T ^c   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACID LIPASE; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ALPHA INTERFERON; CELL CYCLE PROTEIN; CHOLESTEROL ESTERASE; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 1; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DROSOPHILA PROTEIN; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE DEACETYLASE; INTERFERON; ISOPENTENYL DIPHOSPHATE DELTA ISOMERASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; ZINC FINGER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; FATTY ACID SYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEROL METABOLISM; TISSUE CULTURE; TRANSCRIPTION REGULATION; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, NORTHERN; CELL CYCLE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444331074     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol, 1998;10:123-30.
2. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol, 1999;17:1061-70.
3. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res, 2002;8:2035-43.
4. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer, 1999;83:151-6.
5. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med, 1995;332:1004-14.
6. Ling V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer, 1992;69:2603-9.
7. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β -tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem, 1997;272:17118-25.
8. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest, 1997;100:1282-93.
9. Kasai T, Iwanaga Y, Iha H, Jeang KT. Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem, 2002;277:5187-93.
10. 2-M arrest and apoptosis. Nat Med, 1996;2:72-9.
11. Wu GS, El-Diery WS. p53 and chemosensitivity. Nat Med, 1996;2: 255-6.
12. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet, 2000;24:236-44.
13. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA, 2001;98:10787-92.
14. Dan S, Tsunoda T, Kitahara O, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res, 2002;62:1139-47.
15. Giovanella BC, Stehlin JS Jr, Shepard RC, Williams LJ Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer, 1983;52:1146-52.
16. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer, 2001;84:1424-31.
17. Eva A, Robbins KC, Andersen PR, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumor cells. Nature, 1982; 295:116-9.
18. Benard J, Da Silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res, 1985;45:4970-9.
19. Massazza G, Tomasoni A, Lucchini V, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer, 1989;44:494-500.
20. Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res, 1998;4:1977-83.
21. Nicoletti MI, Valoti G, Giannakakou P, et al. Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res, 2001;7: 2912-22.
22. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA, 1990;87:1663-7.
23. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst, 2002;94:990-1000.
24. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000; 403:503-11.
25. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature, 2000;406:747-52.
26. Codegoni AM, Nicoletti MI, Buraggi G, et al. Molecular characterization of a panel of human ovarian carcinoma xenografts. Eur J Cancer, 1998;34:1432-8.
27. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA, 1984;81:1991-5.
28. Vikhanskaya F, Bani MR, Borsotti P, et al. p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001;20:7293-300.
29. Erba E, Serafini M, Gaipa G, et al. Effect of Aplidin in acute lymphoblastic leukemia cells. Br J Cancer, 2003;89:763-73.
30. Nicoletti MI, Colombo T, Rossi C, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res, 2000;60:842-6.
31. Taraboletti G, Micheletti G, Rieppi M, et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res, 2002;8:1182-8.
32. Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs, 1992;3:311-21.
33. Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res, 2002;62:1935-8.
34. Lasorella A, Iavarone A, Israel MA. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol, 1996;16:2570-8.
35. Letwin K, Mizzen L, Motro B, Ben-David Y, Bernstein A, Pawson T. A mammalian dual specificity protein kinase, Nek1, is related to the NIMA cell cycle regulator and highly expressed in meiotic germ cells. EMBO J, 1992;11:3521-31.
36. Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-β/bone morphogenetic protein family. J Biol Chem, 1998;273:13760-7.
37. 1 cyclin-dependent kinases. Cell, 1993;75:805-16.
38. Riabowol K, Draetta G, Brizuela L, Vandre D, Beach D. The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell, 1989;57:393-401.
39. Escargueil AE, Plisov SY, Skladanowski A, et al. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J, 2001;15:2288-90.
40. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature, 1997;389:300-5.
41. Boyd JM, Malstrom S, Subramanian T, et al. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell, 1994;79:341-51.
42. Balcer-Kubiczek EK, Zhang XF, Han LH, et al. BIGEL analysis of gene expression in HL60 cells exposed to X rays or 60 Hz magnetic fields. Radiat Res, 1998;150:663-72.
43. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages. J Leukoc Biol, 1992;52:119-21.
44. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res, 1999;5:3445-53.
45. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA, 1998;95:3896-901.
46. Kawasaki H, Schiltz L, Chiu R, et al. ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature, 2000;405:195-200.
47. Hemavathy K, Guru SC, Harris J, Chen JD, Ip YT. Human Slug is a repressor that localizes to sites of active transcription. Mol Cell Biol, 2000;20:5087-95.
48. Dangond F, Hafler DA, Tong JK, et al. Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem Biophys Res Commun, 1998;242:648-52.
49. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA, 1999;96:4592-7.
50. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA, 2002;99: 11700-5.
51. Moss J, Vaughan M. Molecules in the ARF orbit. J Biol Chem, 1998; 273:21431-4.
52. Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell, 1999;96:655-65.
53. Wilkie TM, Gilbert DJ, Olsen AS, et al. Evolution of the mammalian G protein α subunit multigene family. Nat Genet, 1992; 1:85-91.
54. Peng Y, Du K, Ramirez S, Diamond RH, Taub R. Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. J Biol Chem, 1999;274: 4513-20.
55. Ostermann J, Orci L, Tani K, et al. Stepwise assembly of functionally active transport vesicles. Cell, 1993;75:1015-25.
56. Dell KR, Turck CW, Vale RD. Mitotic phosphorylation of the dynein light intermediate chain is mediated by cdc2 kinase. Traffic, 2000;1:38-44.
57. Luker KE, Pica CM, Schreiber RD, Piwnica-Worms D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res, 2001;61:6540-7.
58. Shanker K, Pathak NK, Trivedi VP, Chansuria JP, Pandey VB. An evaluation of toxicity of Taxus baccata Linn. (Talispatra) in experimental animals. J Ethnopharmacol, 2002;79:69-73.
59. Benard J, Da Silva J, Teyssier JR, Riou G. Over-expression of MDR1 gene with no DNA amplification in a multiple-drug-resistant human ovarian carcinoma cell line. Int J Cancer, 1989;43:471-7.
60. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene, 2000; 19:3078-85.
61. Zembutsu H, Ohnishi Y, Tsunoda T, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res, 2002;62:518-27.